| Literature DB >> 32883234 |
Yunying Zhou1,2,3,4, Fengyan Pei1,3, Mingyu Ji1,3, Fang Zhang1,3, Yingshuo Sun1, Qianqian Zhao1,3, Xiao Wang1,3, Yatian Hong1,3, Juanjuan Tian1,3, Yunshan Wang5,6,7, Jason J Chen8.
Abstract
BACKGROUND: Genomic instability is a hallmark of cancer. The G1 checkpoint allows cells to repair damaged DNA that may lead to genomic instability. The high-risk human papillomavirus (HPV) E7 gene can abrogate the G1 checkpoint, yet the mechanism is still not fully understood. Our recent study showed that WDHD1 (WD repeat and high mobility group [HMG]-box DNA-binding protein 1) plays a role in regulating G1 checkpoint of E7 expressing cells. In this study, we explored the mechanism by which WDHD1 regulates G1 checkpoint in HPV E7 expressing cells.Entities:
Keywords: G1 arrest; GCN5; HPV; P-Akt; WDHD1
Mesh:
Substances:
Year: 2020 PMID: 32883234 PMCID: PMC7469104 DOI: 10.1186/s12885-020-07287-1
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
The sequence of siRNA duplexes
Fig. 1GCN5 mRNA expression correlates with WDHD1. a GCN5 and WDHD1 mRNA levels in NIKs cells determined by RNA-seq. b and c GCN5 and WDHD1 mRNA levels in NIKS and RPE1 cells determined by real-time PCR. Error bars reflect the standard deviations of the mean. *, p < 0.05 **, p < 0.01
Fig. 2GCN5 protein expression correlates with WDHD1. a GCN5 and WDHD1 protein levels in RPE1 cells. b GCN5 protein levels in RPE1 E7 cells examined by Western blotting after retransfected with Flag-WDHD1. Data were summarized (Right panel). c RPE1 cells were incubated with cycloheximide (CHX) and harvested at the indicated times. The stability of GCN5 was monitored by immunoblotting analyses (left panel). Data are summarized in the right panel. Data from a representative experiment of 3 are shown, *P < 0.05; **P < 0.01. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 2
Fig. 3Over expression of GCN5 rescues DNA replication reduction induced by WDHD1 depletion. a RPE1 cells expressing E7 were transfected with Flag-GCN5 or flag after WDHD1 siRNA transfection, and then cells treated with bleomycin for 36 h. Western blotting was used to determine the steady-state level of GCN5. Tubulin was used as a loading control. Right panel, quantification of relative GCN5 levels from 3 independent experiments. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 3A. b Cells were stained with PI after bleomycin treatment. G1, S and G2 phases are indicated and quantified. c Cells were stained with BrdU after bleomycin treatment, and analyzed by flow cytometry. Data from a representative experiment of 3 were shown. Error bars reflect the standard deviations of the mean. NC, negative control. *P < 0.05; **P < 0.01
Fig. 4WDHD1 activates p-Akt expression to modulate cell cycle progression by up-regulating GCN5 in HPV E7 expressing cells. a The steady state levels of p-Akt by Western blot after GCN5 interference in RPE1 cells. b The steady state levels of p-Akt and GCN5 by Western blot after WDHD1 interference in RPE1 cells. c RPE1-E7 expressing cells were transfected with Flag-GCN5 or flag after WDHD1 siRNA transfection. The steady-state levels of p-Akt and GCN5 were measured by Western blotting. Tubulin was used as a loading control. Right panel, quantification of relative p-Akt levels from 3 independent experiments. Error bars reflect the standard deviations of the mean. NC, negative control. *P < 0.05; **P < 0.01. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 4